| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Corpus Striatum | 10 | 2018 | 49 | 3.90 | Why? |
| Dyskinesia, Drug-Induced | 5 | 2018 | 20 | 2.50 | Why? |
| Levodopa | 7 | 2018 | 87 | 2.22 | Why? |
| Neuronal Plasticity | 9 | 2018 | 98 | 2.10 | Why? |
| Parkinson Disease | 14 | 2018 | 1414 | 2.05 | Why? |
| Receptors, Dopamine D2 | 5 | 2018 | 22 | 2.01 | Why? |
| Antiparkinson Agents | 7 | 2018 | 125 | 2.00 | Why? |
| Dopamine | 7 | 2018 | 123 | 1.61 | Why? |
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2018 | 13 | 1.47 | Why? |
| Synapses | 6 | 2018 | 83 | 1.41 | Why? |
| Basal Ganglia | 3 | 2018 | 49 | 1.40 | Why? |
| Synaptic Transmission | 7 | 2019 | 46 | 1.33 | Why? |
| Dopaminergic Neurons | 2 | 2018 | 59 | 1.21 | Why? |
| alpha-Synuclein | 6 | 2018 | 71 | 1.17 | Why? |
| Long-Term Potentiation | 6 | 2019 | 19 | 1.15 | Why? |
| Hippocampus | 4 | 2019 | 237 | 1.13 | Why? |
| Migraine with Aura | 2 | 2019 | 33 | 0.93 | Why? |
| Parkinsonian Disorders | 3 | 2018 | 118 | 0.92 | Why? |
| Glutamic Acid | 3 | 2018 | 65 | 0.84 | Why? |
| Epilepsies, Partial | 1 | 2020 | 44 | 0.82 | Why? |
| Heavy Metal Poisoning | 1 | 2018 | 17 | 0.76 | Why? |
| Mesencephalon | 1 | 2018 | 12 | 0.74 | Why? |
| Optogenetics | 1 | 2017 | 5 | 0.71 | Why? |
| Neuroprotection | 1 | 2018 | 62 | 0.70 | Why? |
| Medicine in the Arts | 1 | 2019 | 58 | 0.69 | Why? |
| Neurotoxicity Syndromes | 1 | 2018 | 124 | 0.69 | Why? |
| Receptors, N-Methyl-D-Aspartate | 3 | 2017 | 81 | 0.67 | Why? |
| Movement Disorders | 1 | 2019 | 186 | 0.63 | Why? |
| Cholinergic Neurons | 1 | 2015 | 9 | 0.62 | Why? |
| Status Epilepticus | 1 | 2020 | 303 | 0.61 | Why? |
| Alzheimer Disease | 4 | 2018 | 1020 | 0.60 | Why? |
| Cognition Disorders | 2 | 2018 | 574 | 0.59 | Why? |
| Energy Metabolism | 1 | 2018 | 451 | 0.53 | Why? |
| Epilepsy | 4 | 2018 | 1401 | 0.52 | Why? |
| Central Nervous System | 2 | 2018 | 701 | 0.50 | Why? |
| Stroke | 6 | 2021 | 8839 | 0.49 | Why? |
| Neuroprotective Agents | 4 | 2018 | 240 | 0.38 | Why? |
| Brain Ischemia | 3 | 2020 | 2813 | 0.38 | Why? |
| Neostriatum | 2 | 2015 | 6 | 0.37 | Why? |
| Delivery of Health Care, Integrated | 1 | 2020 | 1549 | 0.36 | Why? |
| Neurons | 4 | 2018 | 864 | 0.36 | Why? |
| Motor Activity | 3 | 2018 | 217 | 0.33 | Why? |
| Cerebral Cortex | 3 | 2017 | 276 | 0.33 | Why? |
| Nerve Tissue Proteins | 2 | 2017 | 319 | 0.33 | Why? |
| Demyelinating Diseases | 2 | 2018 | 224 | 0.30 | Why? |
| Multiple Sclerosis | 2 | 2018 | 2600 | 0.29 | Why? |
| Animals | 25 | 2020 | 78931 | 0.29 | Why? |
| Dopamine Agonists | 3 | 2018 | 61 | 0.29 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.28 | Why? |
| Quinpirole | 2 | 2018 | 4 | 0.27 | Why? |
| Anticonvulsants | 2 | 2018 | 634 | 0.24 | Why? |
| Amyloid beta-Peptides | 3 | 2018 | 185 | 0.24 | Why? |
| Calcium | 2 | 2018 | 708 | 0.23 | Why? |
| Sodium-Potassium-Exchanging ATPase | 2 | 2019 | 46 | 0.23 | Why? |
| Cognitive Dysfunction | 3 | 2018 | 1389 | 0.23 | Why? |
| Neuropsychological Tests | 2 | 2017 | 954 | 0.23 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2018 | 529 | 0.22 | Why? |
| Interneurons | 1 | 1999 | 13 | 0.21 | Why? |
| Brain | 5 | 2020 | 5133 | 0.20 | Why? |
| Medical Illustration | 1 | 2019 | 35 | 0.20 | Why? |
| GTP-Binding Proteins | 2 | 2017 | 132 | 0.20 | Why? |
| Mice | 7 | 2019 | 21357 | 0.20 | Why? |
| Clomipramine | 1 | 2018 | 12 | 0.20 | Why? |
| Mice, Transgenic | 2 | 2018 | 2739 | 0.20 | Why? |
| Amitriptyline | 1 | 2018 | 31 | 0.20 | Why? |
| Cerebral Small Vessel Diseases | 1 | 2020 | 89 | 0.20 | Why? |
| Receptors, Glutamate | 1 | 2018 | 9 | 0.19 | Why? |
| Excitatory Postsynaptic Potentials | 1 | 2018 | 9 | 0.19 | Why? |
| Antidepressive Agents, Tricyclic | 1 | 2018 | 29 | 0.19 | Why? |
| Migraine Disorders | 3 | 2018 | 530 | 0.19 | Why? |
| CA1 Region, Hippocampal | 1 | 2018 | 12 | 0.19 | Why? |
| Urea Cycle Disorders, Inborn | 1 | 2018 | 1 | 0.19 | Why? |
| Neurology | 2 | 2021 | 1613 | 0.18 | Why? |
| Mice, Mutant Strains | 1 | 2018 | 42 | 0.18 | Why? |
| Art | 1 | 2019 | 37 | 0.18 | Why? |
| Cognition | 2 | 2018 | 1394 | 0.18 | Why? |
| Post-Synaptic Density | 1 | 2017 | 2 | 0.18 | Why? |
| Phlebitis | 1 | 2017 | 3 | 0.18 | Why? |
| Nystagmus, Pathologic | 1 | 2018 | 30 | 0.18 | Why? |
| Piracetam | 1 | 2017 | 6 | 0.18 | Why? |
| Glucosylceramidase | 1 | 2017 | 11 | 0.18 | Why? |
| Fatty Acid Binding Protein 3 | 1 | 2017 | 17 | 0.18 | Why? |
| Hashimoto Disease | 1 | 2018 | 74 | 0.18 | Why? |
| Infarction, Middle Cerebral Artery | 1 | 2020 | 203 | 0.17 | Why? |
| Spatial Memory | 1 | 2017 | 7 | 0.17 | Why? |
| Patient Dropouts | 1 | 2018 | 96 | 0.17 | Why? |
| Rats | 5 | 2017 | 2764 | 0.17 | Why? |
| Lewy Body Disease | 1 | 2017 | 36 | 0.17 | Why? |
| Brain Chemistry | 1 | 2017 | 49 | 0.17 | Why? |
| Vestibular Diseases | 1 | 2018 | 68 | 0.17 | Why? |
| Receptors, Metabotropic Glutamate | 1 | 1996 | 6 | 0.17 | Why? |
| Headache Disorders, Secondary | 1 | 2018 | 56 | 0.17 | Why? |
| Second Messenger Systems | 1 | 1996 | 14 | 0.17 | Why? |
| Vertigo | 1 | 2018 | 141 | 0.17 | Why? |
| Ion Channel Gating | 1 | 1996 | 22 | 0.17 | Why? |
| Vesicular Transport Proteins | 1 | 2017 | 110 | 0.16 | Why? |
| Oxidopamine | 3 | 2017 | 9 | 0.16 | Why? |
| Psychomotor Performance | 1 | 2017 | 110 | 0.16 | Why? |
| Calcium Channels | 1 | 1996 | 96 | 0.16 | Why? |
| Memory, Short-Term | 1 | 2017 | 137 | 0.15 | Why? |
| Mice, Knockout | 2 | 2018 | 1815 | 0.15 | Why? |
| Rats, Sprague-Dawley | 2 | 2017 | 987 | 0.15 | Why? |
| Transcranial Magnetic Stimulation | 1 | 2017 | 160 | 0.15 | Why? |
| Electroencephalography | 2 | 2020 | 1242 | 0.15 | Why? |
| History, 20th Century | 2 | 2019 | 1282 | 0.15 | Why? |
| Animals, Genetically Modified | 1 | 2015 | 230 | 0.14 | Why? |
| Astrocytes | 1 | 2017 | 298 | 0.14 | Why? |
| Humans | 54 | 2021 | 930598 | 0.14 | Why? |
| Dependovirus | 1 | 2015 | 272 | 0.14 | Why? |
| Nerve Growth Factors | 1 | 2013 | 30 | 0.13 | Why? |
| Vision Disorders | 1 | 2017 | 260 | 0.13 | Why? |
| Nose | 1 | 2020 | 1093 | 0.13 | Why? |
| Microglia | 1 | 2017 | 357 | 0.13 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 502 | 0.13 | Why? |
| Mice, Inbred C57BL | 3 | 2018 | 5542 | 0.12 | Why? |
| Diagnosis, Differential | 4 | 2020 | 7220 | 0.12 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.12 | Why? |
| tau Proteins | 3 | 2017 | 162 | 0.12 | Why? |
| Intracranial Hemorrhages | 1 | 2021 | 1170 | 0.12 | Why? |
| Magnetic Resonance Imaging | 5 | 2020 | 6551 | 0.12 | Why? |
| Signal Transduction | 1 | 2009 | 7207 | 0.11 | Why? |
| Nervous System Diseases | 2 | 2020 | 4092 | 0.11 | Why? |
| Encephalitis | 1 | 2018 | 797 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Brain Neoplasms | 1 | 2017 | 669 | 0.10 | Why? |
| Substantia Nigra | 1 | 2009 | 22 | 0.10 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.10 | Why? |
| Thrombectomy | 1 | 2021 | 2272 | 0.10 | Why? |
| Learning | 1 | 2018 | 1181 | 0.10 | Why? |
| Rats, Wistar | 2 | 2017 | 621 | 0.09 | Why? |
| Models, Animal | 2 | 2020 | 788 | 0.09 | Why? |
| Mutation | 3 | 2019 | 12376 | 0.09 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.09 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.09 | Why? |
| Male | 29 | 2021 | 367725 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Female | 26 | 2021 | 380317 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Tissue Culture Techniques | 2 | 2018 | 158 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Aged | 18 | 2021 | 215776 | 0.08 | Why? |
| Nipecotic Acids | 1 | 2006 | 2 | 0.08 | Why? |
| Excitatory Amino Acid Agonists | 1 | 2006 | 8 | 0.08 | Why? |
| Methylprednisolone | 1 | 2018 | 2107 | 0.08 | Why? |
| N-Methylaspartate | 1 | 2006 | 13 | 0.08 | Why? |
| Vigabatrin | 1 | 2006 | 44 | 0.08 | Why? |
| Deep Brain Stimulation | 1 | 2009 | 203 | 0.08 | Why? |
| Recombinant Proteins | 1 | 2015 | 3786 | 0.07 | Why? |
| Statistics as Topic | 2 | 2017 | 370 | 0.07 | Why? |
| gamma-Aminobutyric Acid | 1 | 2004 | 52 | 0.07 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.06 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.06 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.06 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.06 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.06 | Why? |
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2001 | 1 | 0.06 | Why? |
| Receptors, Dopamine D1 | 1 | 2001 | 9 | 0.06 | Why? |
| Reproducibility of Results | 4 | 2021 | 11304 | 0.06 | Why? |
| Retina | 1 | 2006 | 424 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.05 | Why? |
| Speech Disorders | 1 | 2020 | 55 | 0.05 | Why? |
| Hospitals, Low-Volume | 1 | 2021 | 355 | 0.05 | Why? |
| Depressive Disorder | 1 | 2011 | 1236 | 0.05 | Why? |
| Paresis | 1 | 2020 | 77 | 0.05 | Why? |
| Evoked Potentials | 2 | 1997 | 44 | 0.05 | Why? |
| Electric Stimulation | 2 | 1997 | 84 | 0.05 | Why? |
| Creutzfeldt-Jakob Syndrome | 1 | 2018 | 35 | 0.05 | Why? |
| Amino-Acid N-Acetyltransferase | 1 | 2018 | 1 | 0.05 | Why? |
| Synapsins | 1 | 2018 | 9 | 0.05 | Why? |
| Synaptophysin | 1 | 2018 | 7 | 0.05 | Why? |
| Dopamine Uptake Inhibitors | 1 | 2018 | 9 | 0.05 | Why? |
| Tyrosine 3-Monooxygenase | 1 | 2018 | 32 | 0.05 | Why? |
| Membrane Potentials | 1 | 2018 | 56 | 0.05 | Why? |
| Dopamine Antagonists | 1 | 2018 | 13 | 0.05 | Why? |
| Glutamates | 1 | 2018 | 12 | 0.05 | Why? |
| Neural Pathways | 1 | 1999 | 155 | 0.05 | Why? |
| Dopamine Plasma Membrane Transport Proteins | 1 | 2018 | 37 | 0.05 | Why? |
| beta-N-Acetylhexosaminidases | 1 | 2017 | 10 | 0.05 | Why? |
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2017 | 12 | 0.05 | Why? |
| 2-Amino-5-phosphonovalerate | 1 | 1997 | 3 | 0.05 | Why? |
| Cathepsin D | 1 | 2017 | 8 | 0.04 | Why? |
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1997 | 3 | 0.04 | Why? |
| Crosses, Genetic | 1 | 1997 | 13 | 0.04 | Why? |
| Reaction Time | 1 | 2018 | 96 | 0.04 | Why? |
| Genes, Immediate-Early | 1 | 2017 | 1 | 0.04 | Why? |
| Italy | 5 | 2021 | 38444 | 0.04 | Why? |
| Adrenergic Agents | 1 | 2017 | 7 | 0.04 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.04 | Why? |
| Visual Pathways | 1 | 2017 | 21 | 0.04 | Why? |
| Benzazepines | 1 | 2018 | 49 | 0.04 | Why? |
| Sulpiride | 1 | 1997 | 11 | 0.04 | Why? |
| Putamen | 1 | 2017 | 24 | 0.04 | Why? |
| Parkinson Disease, Secondary | 1 | 1997 | 15 | 0.04 | Why? |
| Supranuclear Palsy, Progressive | 1 | 2017 | 20 | 0.04 | Why? |
| Theta Rhythm | 1 | 2017 | 10 | 0.04 | Why? |
| Patch-Clamp Techniques | 1 | 2017 | 49 | 0.04 | Why? |
| Microdialysis | 1 | 2017 | 22 | 0.04 | Why? |
| NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 4 | 0.04 | Why? |
| Motor Skills | 1 | 2018 | 57 | 0.04 | Why? |
| Hospitals, High-Volume | 1 | 2021 | 688 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Macaca mulatta | 2 | 2017 | 3716 | 0.04 | Why? |
| Nerve Fibers | 1 | 1997 | 73 | 0.04 | Why? |
| Databases, Bibliographic | 1 | 2017 | 182 | 0.04 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.04 | Why? |
| Neuromuscular Diseases | 1 | 2020 | 303 | 0.04 | Why? |
| Peptide Fragments | 2 | 2017 | 2075 | 0.04 | Why? |
| Green Fluorescent Proteins | 1 | 2018 | 450 | 0.04 | Why? |
| Ischemic Attack, Transient | 1 | 2021 | 439 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| Mental Status and Dementia Tests | 1 | 2017 | 208 | 0.04 | Why? |
| Heterozygote | 1 | 1997 | 249 | 0.04 | Why? |
| Behavior, Animal | 1 | 2017 | 136 | 0.04 | Why? |
| Anniversaries and Special Events | 1 | 2017 | 127 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Age of Onset | 1 | 2018 | 557 | 0.04 | Why? |
| Dizziness | 1 | 2018 | 275 | 0.04 | Why? |
| History, 19th Century | 1 | 2017 | 384 | 0.04 | Why? |
| In Vitro Techniques | 2 | 1997 | 1027 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.04 | Why? |
| ROC Curve | 2 | 2017 | 6024 | 0.04 | Why? |
| Magnesium | 1 | 1997 | 290 | 0.03 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.03 | Why? |
| Lysosomes | 1 | 2017 | 416 | 0.03 | Why? |
| Analgesics | 1 | 2018 | 451 | 0.03 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.03 | Why? |
| Adult | 12 | 2020 | 244371 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Eye | 1 | 2017 | 374 | 0.03 | Why? |
| Calcium Channel Blockers | 1 | 1996 | 367 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Intracranial Arteriovenous Malformations | 1 | 1992 | 71 | 0.03 | Why? |
| Patients | 1 | 2020 | 1167 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Mycosis Fungoides | 1 | 1971 | 48 | 0.03 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.03 | Why? |
| Antimetabolites | 1 | 1971 | 106 | 0.03 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Phosphoproteins | 1 | 2001 | 4346 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.03 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.03 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.03 | Why? |
| Young Adult | 5 | 2018 | 93724 | 0.02 | Why? |
| Neuroimaging | 1 | 2017 | 1106 | 0.02 | Why? |
| Headache | 1 | 2020 | 2257 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Thrombolytic Therapy | 1 | 2021 | 2218 | 0.02 | Why? |
| Bipolar Disorder | 1 | 2017 | 744 | 0.02 | Why? |
| Triazines | 1 | 1971 | 246 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.02 | Why? |
| Pharmacology | 1 | 1968 | 27 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.02 | Why? |
| Schizophrenia | 1 | 2017 | 1018 | 0.02 | Why? |
| Nursing Staff, Hospital | 1 | 2020 | 1554 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Phenotype | 1 | 1997 | 4037 | 0.02 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.02 | Why? |
| Chick Embryo | 1 | 2006 | 249 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.02 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.02 | Why? |
| Norepinephrine | 1 | 1984 | 152 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Analysis of Variance | 1 | 2006 | 950 | 0.01 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.01 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.01 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.01 | Why? |
| Enzyme Precursors | 1 | 1959 | 7 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Gastric Juice | 1 | 1959 | 7 | 0.01 | Why? |
| Pepsin A | 1 | 1959 | 20 | 0.01 | Why? |
| Thromboembolism | 1 | 1973 | 2101 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Psoriasis | 1 | 1973 | 1739 | 0.01 | Why? |
| Leukemia, Myeloid | 1 | 1959 | 76 | 0.01 | Why? |
| Polycythemia Vera | 1 | 1959 | 113 | 0.01 | Why? |
| Drug Interactions | 1 | 2006 | 1653 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| L-Lactate Dehydrogenase | 1 | 2006 | 1995 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Blood Group Antigens | 1 | 1959 | 202 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Adenocarcinoma | 1 | 1982 | 651 | 0.01 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.01 | Why? |
| Pancreatic Neoplasms | 1 | 1982 | 609 | 0.01 | Why? |
| Leukemia | 1 | 1959 | 598 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Thrombophlebitis | 1 | 1973 | 94 | 0.01 | Why? |
| Orotic Acid | 1 | 1971 | 2 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Rhode Island | 1 | 1973 | 425 | 0.01 | Why? |
| Chemical Phenomena | 1 | 1971 | 22 | 0.01 | Why? |
| Chemistry | 1 | 1971 | 14 | 0.01 | Why? |
| Aspartic Acid | 1 | 1971 | 76 | 0.01 | Why? |
| Hematocrit | 1 | 1971 | 107 | 0.01 | Why? |
| Uracil | 1 | 1971 | 101 | 0.01 | Why? |
| ABO Blood-Group System | 1 | 1959 | 995 | 0.01 | Why? |
| Cerebral Angiography | 1 | 1992 | 391 | 0.01 | Why? |
| Acetates | 1 | 1971 | 123 | 0.01 | Why? |
| Cerebrovascular Circulation | 1 | 1992 | 340 | 0.01 | Why? |
| Purpura | 1 | 1971 | 310 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |
| Comorbidity | 1 | 2011 | 34796 | 0.00 | Why? |
| Domperidone | 1 | 1984 | 4 | 0.00 | Why? |
| Phentolamine | 1 | 1984 | 5 | 0.00 | Why? |
| Blood Cell Count | 1 | 1971 | 1101 | 0.00 | Why? |
| Iontophoresis | 1 | 1984 | 8 | 0.00 | Why? |
| Rats, Inbred Strains | 1 | 1984 | 14 | 0.00 | Why? |
| Cerebrovascular Disorders | 1 | 1973 | 1040 | 0.00 | Why? |
| Timolol | 1 | 1984 | 11 | 0.00 | Why? |
| Neoplasm Transplantation | 1 | 1982 | 55 | 0.00 | Why? |
| Administration, Oral | 1 | 1971 | 2340 | 0.00 | Why? |
| Perfusion | 1 | 1984 | 254 | 0.00 | Why? |
| Neoplasms, Experimental | 1 | 1982 | 67 | 0.00 | Why? |
| Transplantation, Heterologous | 1 | 1982 | 77 | 0.00 | Why? |
| Mice, Nude | 1 | 1982 | 340 | 0.00 | Why? |
| Child | 1 | 2011 | 70012 | 0.00 | Why? |
| Lymphatic Metastasis | 1 | 1982 | 537 | 0.00 | Why? |
| Myocardial Infarction | 1 | 1973 | 3361 | 0.00 | Why? |
| Kidney | 1 | 1971 | 3648 | 0.00 | Why? |
| Liver | 1 | 1971 | 4007 | 0.00 | Why? |
| Lymph Nodes | 1 | 1982 | 1060 | 0.00 | Why? |
| Ultrasonography | 1 | 1992 | 4409 | 0.00 | Why? |
| Pulmonary Embolism | 1 | 1973 | 4775 | 0.00 | Why? |
| Clinical Trials as Topic | 1 | 1968 | 7330 | 0.00 | Why? |
| Lung Neoplasms | 1 | 1982 | 3228 | 0.00 | Why? |